HomeCompareESSA vs JNJ

ESSA vs JNJ: Dividend Comparison 2026

ESSA yields 2.91% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ESSA wins by $349.3K in total portfolio value
10 years
ESSA
ESSA
● Live price
2.91%
Share price
$20.61
Annual div
$0.60
5Y div CAGR
55.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$379.6K
Annual income
$210,681.63
Full ESSA calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ESSA vs JNJ

📍 ESSA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESSAJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESSA + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESSA pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESSA
Annual income on $10K today (after 15% tax)
$247.45/yr
After 10yr DRIP, annual income (after tax)
$179,079.39/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ESSA beats the other by $175,093.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESSA + JNJ for your $10,000?

ESSA: 50%JNJ: 50%
100% JNJ50/50100% ESSA
Portfolio after 10yr
$204.9K
Annual income
$107,685.52/yr
Blended yield
52.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ESSA
No analyst data
Altman Z
-0.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESSA buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESSAJNJ
Forward yield2.91%2.13%
Annual dividend / share$0.60$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR55.8%28%
Portfolio after 10y$379.6K$30.3K
Annual income after 10y$210,681.63$4,689.40
Total dividends collected$341.3K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ESSA vs JNJ ($10,000, DRIP)

YearESSA PortfolioESSA Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,154$453.57$10,592$272.30+$562.00ESSA
2$12,671$736.61$11,289$357.73+$1.4KESSA
3$14,776$1,218.47$12,123$472.89+$2.7KESSA
4$17,880$2,068.99$13,141$629.86+$4.7KESSA
5$22,777$3,645.32$14,408$846.81+$8.4KESSA
6$31,133$6,761.58$16,021$1,151.60+$15.1KESSA
7$46,769$13,457.28$18,122$1,588.22+$28.6KESSA
8$79,479$29,436.46$20,930$2,228.20+$58.5KESSA
9$157,882$72,839.13$24,792$3,191.91+$133.1KESSA
10$379,615$210,681.63$30,274$4,689.40+$349.3KESSA

ESSA vs JNJ: Complete Analysis 2026

ESSAStock

ESSA Bancorp, Inc. operates as a bank holding company for ESSA Bank & Trust that provides a range of financial services to individuals, families, and businesses in Pennsylvania. The company accepts savings accounts, interest bearing demand accounts, checking accounts, money market accounts, club accounts, certificates of deposit and IRAs, and other qualified plan accounts, as well as commercial checking accounts. Its loan portfolio includes first mortgage loans for the purchase, construction, or refinancing of one- to four-family residential real estate property; commercial real estate loans; home equity loans and lines of credit; and commercial and other consumer loans, as well as loans secured by deposits and personal unsecured loans. In addition, the company offers insurance benefits consulting services, such as health insurance, life insurance, short term and long term disability, dental, vision, 401(K) retirement planning, and individual health products, as well as asset management and trust, and investment services. As of September 30, 2021, it operated 21 community offices, including seven offices in Monroe County, three offices in Lehigh County, five offices in Northampton County, one office in Lackawanna County, one office in Luzerne County, one office in Chester County, two offices in Delaware County, and one office in Montgomery County, Pennsylvania. The company was founded in 1916 and is headquartered in Stroudsburg, Pennsylvania.

Full ESSA Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ESSA vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESSA vs SCHDESSA vs JEPIESSA vs OESSA vs KOESSA vs MAINESSA vs ABBVESSA vs MRKESSA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.